Skip to content

Latigo Biotherapeutics

US · LTGO #3230 by market cap Listed 2026
13.00 -0.24 -1.81%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:26

Price chart

Pre-market 13.00 -1.81%
After-hours 13.00 0.00%
25.0012.6013.002026-08-072026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on LTGO?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -39.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 1.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Performance

1W -0.84%
1M -14.75%
3M -39.25%

Key statistics

Price & volume

Prev close
13.24
Open
13.22
Day range
11.91 - 13.35
Avg price
12.99
Volume
267.17K
Turnover
3.47M
Amplitude
10.88%
52-week range
10.24 - 25.93

Valuation

P/E
-7.16
P/E (TTM)
-8.03
P/B
2.19
EPS
-1.82
Net profit
-120.33M
Net assets
393.95M

Share structure

Market cap
861.89M
Float cap
208.00M
Shares out
66.30M
Float shares
16.00M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2026-08-07
52-week range 18% of range
10.24 25.93

49.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-7.10M net over the window

Short interest

Shares short
941.43K
As of
2026-10-30

Frequently asked questions

What is the current stock price of Latigo Biotherapeutics (LTGO)?

Latigo Biotherapeutics last traded at 13.00. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Latigo Biotherapeutics's market cap?

About 861.89M.

What is the P/E ratio of Latigo Biotherapeutics?

The trailing twelve-month P/E is -8.03. The Valuation tab shows it against the stock's own five-year range.

Does Latigo Biotherapeutics pay a dividend?

Latigo Biotherapeutics does not currently pay a regular dividend.

Is Latigo Biotherapeutics a buy according to analysts?

The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 57.67, which implies 343.6% upside from the current price. This is not investment advice.

What is Latigo Biotherapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Latigo Biotherapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 16:26:22 · For reference only, not investment advice and not tailored to your situation.

Latigo Biotherapeutics discussion 0 comments

Add a comment